Aberdeen Group plc Has $23.88 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Aberdeen Group plc lessened its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 12.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 365,933 shares of the specialty pharmaceutical company’s stock after selling 53,166 shares during the quarter. Aberdeen Group plc’s holdings in ANI Pharmaceuticals were worth $23,877,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ANIP. Woodline Partners LP acquired a new stake in ANI Pharmaceuticals in the 1st quarter valued at approximately $11,144,000. Global Alpha Capital Management Ltd. grew its stake in ANI Pharmaceuticals by 17.8% in the first quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company’s stock valued at $49,248,000 after purchasing an additional 111,040 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in ANI Pharmaceuticals in the first quarter valued at approximately $7,030,000. Lisanti Capital Growth LLC grew its stake in ANI Pharmaceuticals by 291.8% in the first quarter. Lisanti Capital Growth LLC now owns 105,425 shares of the specialty pharmaceutical company’s stock valued at $7,058,000 after purchasing an additional 78,515 shares in the last quarter. Finally, AYAL Capital Advisors Ltd bought a new position in ANI Pharmaceuticals in the first quarter valued at approximately $4,467,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ANIP. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Zacks Research upgraded ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Truist Financial raised their price target on ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. HC Wainwright raised their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, Guggenheim raised their price target on ANI Pharmaceuticals from $86.00 to $114.00 and gave the company a “buy” rating in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $99.14.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP opened at $88.61 on Tuesday. The stock has a market cap of $1.92 billion, a P/E ratio of -115.08 and a beta of 0.58. The stock has a 50 day simple moving average of $91.09 and a 200 day simple moving average of $74.24. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. The firm had revenue of $64.48 million for the quarter. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $90.44, for a total value of $4,792,234.72. Following the completion of the transaction, the chief operating officer directly owned 431,920 shares of the company’s stock, valued at $39,062,844.80. The trade was a 10.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew J. Leonard sold 2,528 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 25th. The shares were sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the transaction, the director directly owned 6,864 shares of the company’s stock, valued at $622,015.68. This represents a 26.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 413,430 shares of company stock worth $36,469,342 in the last 90 days. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.